• 1. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azepanes Azepanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azepanes

Professional Introduction to 4-[(azepan-1-yl)methyl]-1,3-thiazol-2-amine (CAS No. 17386-11-7)

4-[(azepan-1-yl)methyl]-1,3-thiazol-2-amine is a significant compound in the field of pharmaceutical chemistry, characterized by its complex molecular structure and diverse potential applications. This compound, identified by the CAS number 17386-11-7, belongs to the class of azepan-based derivatives, which have garnered considerable attention due to their unique pharmacological properties. The presence of both azepane and thiazole moieties in its structure imparts distinct chemical and biological characteristics, making it a subject of intense research interest.

The molecular framework of 4-[(azepan-1-yl)methyl]-1,3-thiazol-2-amine consists of a thiazole ring substituted with an amine group at the 2-position and an azepanylmethyl group at the 4-position. This configuration allows for multiple interactions with biological targets, including enzymes and receptors, which are pivotal in modulating various physiological processes. The flexibility introduced by the azepane ring enhances the compound's ability to fit into binding pockets of target proteins, thereby increasing its binding affinity and selectivity.

In recent years, there has been a surge in research focused on developing novel therapeutic agents that leverage the structural features of heterocyclic compounds. The combination of azepane and thiazole in 4-[(azepan-1-yl)methyl]-1,3-thiazol-2-amine has been explored for its potential in treating a range of diseases, including neurological disorders, infectious diseases, and cancer. The compound's ability to modulate key biological pathways has made it a promising candidate for further investigation.

One of the most compelling aspects of this compound is its role in drug discovery and development. The structural motif of 4-(azepan-1-yl)methyl]-1,3-thiazol-2-am ine has been utilized as a scaffold for designing new molecules with enhanced pharmacological activity. Researchers have employed computational methods to predict how modifications to this scaffold can improve its binding properties and reduce potential side effects. These studies have not only advanced our understanding of molecular interactions but also provided valuable insights into the design of next-generation drugs.

The pharmacological profile of 4-(azepan -1 -yl)methyl]-1 ,3 -thiazol -2 -amine has been extensively studied in vitro and in vivo. Preclinical studies have demonstrated its potential as an inhibitor of various enzymes involved in disease pathways. For instance, it has shown promise in inhibiting kinases that are overexpressed in cancer cells, thereby offering a new therapeutic strategy for oncology applications. Additionally, its interaction with neurotransmitter receptors has been investigated for potential applications in treating neurological conditions such as Alzheimer's disease and Parkinson's disease.

The synthesis of 4-(azepan -1 -yl)methyl]-1 ,3 -thiazol -2 -amine is another area where significant progress has been made. Advanced synthetic methodologies have enabled researchers to produce this compound with high purity and yield, facilitating further pharmacological studies. The development of efficient synthetic routes has also reduced costs associated with production, making it more feasible for large-scale applications in drug development.

In conclusion, 4-(azepan -1 -yl)methyl]-1 ,3 -thiazol -2 -amine (CAS No. 17386-11-7) represents a fascinating compound with immense potential in pharmaceutical research. Its unique structural features and diverse biological activities make it a valuable tool for drug discovery and development. As research continues to uncover new therapeutic applications, this compound is poised to play a crucial role in addressing some of the most challenging medical conditions faced today.

• 17386-10-6(4-[(piperidin-1-yl)methyl]-1,3-thiazol-2-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)